Form 4 for HBIO HARVARD BIOSCIENCE INC

Accepted 2024-03-07 00:00:00 ET · period of report 2024-03-05 · accession 0001193805-24-000334 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2024-03-07	2024-03-05	HBIO	Cote Jennifer	CFO	A - Grant	$0.00	+71.6K	142.9K	+100%	$0
	2024-03-07	2024-03-06	HBIO	Cote Jennifer	CFO	F - Tax	$4.11	-9,920	168.7K	-6%	-$40.8K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-03-05	A	A	35,800	$0.00	178,658	D	—	—	(F3) The number of RSUs represents the target number of RSUs that may be earned based on achievement by the Company of certain performance criteria. The actual number of RSUs awarded may vary between 0% and 150% of the target, depending on the Company's performance. The performance period will end on December 31, 2026.
2	Common	Common Stock	2024-03-05	A	A	35,800	$0.00	142,858	D	—	—	(F2) Represents an award of RSUs that will vest in three equal installments on March 19, 2025, 2026, and 2027.
3	Common	Common Stock	2024-03-06	F	D	9,920	$4.11	168,738	D	—	—	(F1) Shares withheld by the Company solely to cover tax obligations upon the vesting of 29,880 restricted stock units ("RSUs"). (F4) Includes (a) the awards described in footnotes (2) and (3) above, (b) 17,928 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (c) 11,171 RSUs that will vest on December 29, 2024, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 42,177 shares of common stock beneficially owned by the Reporting Person.